Bioinformatics-driven insights: rapamycin-mediated CaMK2D inhibition alleviates intestinal ischemia-reperfusion injury
-
By
-
Ruxiang Sheng
-
Yanqiu Liang
-
Huihong Zhang
-
Yonghe Lai
-
Haiyun Hong
-
Dingbang Huang
-
Dezhao Liu
-
May 1, 2026
-
Clinical Scorecard: Insights from Bioinformatics: Inhibition of CaMK2D by Rapamycin Mitigates Intestinal Ischemia-Reperfusion Injury
At a Glance
| Category | Detail |
|---|
| Condition | Intestinal Ischemia-Reperfusion Injury |
| Key Mechanisms | Inhibition of CaMK2D signaling pathway by rapamycin reduces inflammation and apoptosis in intestinal epithelial cells. |
| Target Population | Patients experiencing intestinal ischemia-reperfusion injury due to trauma, infection, or surgical procedures. |
| Care Setting | Acute care settings, including emergency departments and surgical units. |
Key Highlights
- CaMK2D hyperactivation is linked to intestinal epithelial apoptosis and barrier impairment during I/R.
- Rapamycin treatment significantly reduces CaMK2D expression and pro-inflammatory cytokines.
- Targeted delivery of rapamycin improves intestinal integrity and mitigates injury in murine models.
Guideline-Based Recommendations
Diagnosis
- Clinical assessment of intestinal ischemia-reperfusion injury based on symptoms and imaging.
Management
- Utilization of rapamycin to inhibit CaMK2D signaling as a therapeutic strategy.
Monitoring & Follow-up
- Regular evaluation of inflammatory markers and intestinal barrier function post-treatment.
Risks
- Potential for high mortality rates (up to 50%) if ischemia-reperfusion injury is not effectively managed.
Patient & Prescribing Data
Individuals with acute intestinal ischemia-reperfusion injury.
Rapamycin (1.5 mg/kg, i.p.) shows promise in reducing injury and improving outcomes.
Clinical Best Practices
- Incorporate bioinformatics approaches to identify therapeutic targets in intestinal I/R injury.
- Consider the use of nano-delivery systems for targeted drug administration.
References
